Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective therapy in patients with advanced colorectal cancer

Anti-Cancer Drugs

Volumn 9, Issue 4, 1998, Pages 301-305

  Gerard, B ^a   Bleiberg, H ^a   Van Daele, D ^b   Gil, Th ^a   Hendlisz, A ^a   Di Leo, A ^a   Fernez, B ^a   Brienza, S ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b CHU d'Lxelles   (Belgium)

^c DEBIOPHARM France   (France)

Author keywords

5 Fluorouracil; Colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PARESTHESIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031747923     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199804000-00002     Document Type: Article

References (20)

1. Mamenta EL, Poma EE, Kaufmann WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54: 3500-5.
2. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
3. Woynarwski JM, Chapman WG, Napier C, et al. Oxaliplatin effects on noked and intracellular DNA. Proc Am Ass Cancer Res 1997; 38: 311.
4. Brienza S, Vignoud J, Itzhaki M, Krikorian A. Oxaliplatin (L-OHP): global safety in 682 patients. Proc Am Soc Clin Oncol 1995; 14: 209.
5. Extra JM, Espié M, Calvo F, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
6. Becouarn Y, Ychou M, Ducreux M, et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1997; 16: 229a.
7. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase two studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
8. Raymond E, Djelloul C, Buquet-Fagot F, et al. Oxaliplatin (L-OHP) and cisplatin (CDDP) in combination with 5-FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694) and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers (meeting abstract). Proc Am Ass Cancer Res 1996; 291: 37.
9. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
10. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-9.
11. Ardalan B, Chua L, Hudes GR, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625-30.
12. Caussanel JP, Lévi F, Brienza S, et al. Phase-I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-50.
13. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5.
14. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
15. de Gramont A, Bosset JF, Milan C, et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 1997; 15: 805-15.
16. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer: a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
17. Weh HJ, Wilke J, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-7.
18. Vancutsem E, Cunningham D, Ten Bokkel Huinink W, et al. Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5FU: preliminary results. Proc Am Soc Clin Oncol 1996; 15: 230.
19. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the 'No Change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Clin Oncol 1996; 24: 1557-72.
20. Graf W, Pahlman L, Bergstrom R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-63.